Should I be buying Unilever shares at the current price?

With Unilever shares having taken a hit in 2022, Charlie Keough looks at if now is the time to be adding the stock to his portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

The last month has seen global consumer goods company Unilever’s (LSE: ULVR) share price rise nearly 6%. However, year-to-date, the stock is down 12%. The firm owns a variety of popular brands, including Sure, Vaseline, and Ben & Jerry’s.

So, with the Unilever share price down in 2022, is this an opportunity for me to add the stock to my portfolio? Let’s take a look.

Why is the share price down?

Let’s begin by taking a look at why the Unilever share price is falling. To start, the firm has been largely impacted by rising inflation. It has seen its costs rise and coupled with the firm failing to grow its sales volumes, it’s clear to see why the stock has struggled.

Chief executive Alan Jope recently mentioned how inflation will be one of the biggest challenges the business faces this year. And, as such, the firm expects between 140 to 240 basis points to be hacked off its underlying operating margin. This will most certainly have an adverse impact on the price of Unilever shares.

It has also come under large pressure from investors of late. This includes issues surrounding new targets for selling more healthy foods. And further pressure was applied after its recent failed bid for GlaxoSmithKline’s consumer healthcare division. With its bid in the region of £50bn, shareholders deemed the move unsustainable given the firm’s financial position. With many holding a preference for focusing on sales and profit growth, the Unilever share price dropped 11% as a result.

Wider outlook

However, there are wider issues I must consider when looking at Unilever.

One positive is that its risk is diversified. The business has global sales and a solid distribution network. It also owns strong brands and has established relationships with retailers. From this point of view, Unilever shares seem a solid buy.

As well as this, RBC recently increased its price target for the firm from 3,400p to 3,600p. In part due to its solid recovery post-Covid, it was also because of the recent stake built up by Nelson Peltz’s activist hedge fund Trian Partners. With a history of streamlining consumer goods groups, this could provide Unilever with a boost in the future.

Should I buy?

So, where do I stand regarding Unilever? I think in the near term the firm will face a variety of issues. For example, inflation will hurt the business. And should it continue to rise, I think the Unilever share price could drop even further. Pressure from shareholders is also an issue. Should their trust in management continue to weaken, we may begin to see more investors offload shares.

However, these are short-term issues. Unilever has a strong fundamental business structure. And the presence of Trian should help guide the firm in the right direction. Because of this, I would be willing to add a speculative amount of Unilever shares to my portfolio.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Charlie Keough has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »